Chen Shyi-Jou, Wang Yen-Ling, Fan Hueng-Chuen, Lo Wen-Tsung, Wang Chih-Chien, Sytwu Huey-Kang
Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Clin Dev Immunol. 2012;2012:970789. doi: 10.1155/2012/970789. Epub 2011 Dec 6.
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, and CD4(+) T cells form the core immunopathogenic cascade leading to chronic inflammation. Traditionally, Th1 cells (interferon-γ-producing CD4(+) T cells) driven by interleukin 12 (IL12) were considered to be the encephalitogenic T cells in MS and experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Currently, Th17 cells (Il17-producing CD4(+) T cells) are considered to play a fundamental role in the immunopathogenesis of EAE. This paper highlights the growing evidence that Th17 cells play the core role in the complex adaptive immunity of EAE/MS and discusses the roles of the associated immune cells and cytokines. These constitute the modern immunological basis for the development of novel clinical and preclinical immunomodulatory therapies for MS discussed in this paper.
多发性硬化症（MS）是一种中枢神经系统的自身免疫性疾病，CD4(+) T细胞形成导致慢性炎症的核心免疫致病级联反应。传统上，由白细胞介素12（IL12）驱动的Th1细胞（产生干扰素-γ的CD4(+) T细胞）被认为是MS和实验性自身免疫性脑脊髓炎（EAE，MS的动物模型）中的致脑炎性T细胞。目前，Th17细胞（产生Il17的CD4(+) T细胞）被认为在EAE的免疫发病机制中起基本作用。本文强调了越来越多的证据表明Th17细胞在EAE/MS的复杂适应性免疫中起核心作用，并讨论了相关免疫细胞和细胞因子的作用。这些构成了本文所讨论的MS新型临床和临床前免疫调节疗法发展的现代免疫学基础。
